Andrew Kuykendall, MD

Andrew Kuykendall, MD, of the Moffitt Cancer Center

Andrew Kuykendall, MD, is an assistant member in the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, Florida.

Articles by Andrew Kuykendall, MD

Andrew Kuykendall, MD

Dr Kuykendall on Molecular Testing in Systemic Mastocytosis

ByAndrew Kuykendall, MD

April 5th 2023

Andrew Kuykendall, MD, discusses the importance of testing for mutations in KIT and other genes in patients with systemic mastocytosis.

Andrew Kuykendall, MD

Dr. Kuykendall on the Investigation of Navitoclax Plus Ruxolitinib in Myelofibrosis

ByAndrew Kuykendall, MD

February 15th 2023

Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.

Andrew Kuykendall, MD

Dr. Kuykendall on the Evaluation of Momelotinib in Myelofibrosis

ByAndrew Kuykendall, MD

February 3rd 2023

Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.

Andrew Kuykendall, MD

Dr. Kuykendall on Treatment Considerations with Ruxolitinib in Myelofibrosis

ByAndrew Kuykendall, MD

October 24th 2022

Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.

Andrew Kuykendall, MD

Dr. Kuykendall on Prognostication Factors in Myelofibrosis

ByAndrew Kuykendall, MD

September 29th 2022

Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.

Trending on OncLive

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’

Real-World Data Reinforce Liso-Cel Efficacy in R/R MCL